Show simple item record

dc.contributor.authorPors, Klaus*
dc.contributor.authorGoldberg, F.W.*
dc.contributor.authorLeamon, C.P.*
dc.contributor.authorRigby, A.C.*
dc.contributor.authorSnyder, S.A.*
dc.contributor.authorFalconer, Robert A.*
dc.date.accessioned2016-08-17T14:34:07Z
dc.date.available2016-08-17T14:34:07Z
dc.date.issued2009-11
dc.identifier.citationPors K, Goldberg FW, Leamon CP et al (2009) The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discovery Today. 14 (21/22): 1045-50.
dc.identifier.urihttp://hdl.handle.net/10454/8821
dc.descriptionNo
dc.description.abstractSince the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.
dc.language.isoen
dc.subjectMedicinal chemistry
dc.subjectChemical biology
dc.subjectDiversity-oriented synthesis
dc.subjectEPSRC
dc.subjectGovernment funding
dc.subjectNCI
dc.subjectCancer drug discovery
dc.titleThe changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
dc.status.refereedYes
dc.typeArticle
dc.type.versionNo full-text in the repository
dc.identifier.doihttps://doi.org/10.1016/j.drudis.2009.07.004
dc.openaccess.statusclosedAccess


This item appears in the following Collection(s)

Show simple item record